Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Csernok, E.
Right arrow Articles by Gross, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Csernok, E.
Right arrow Articles by Gross, W. L.
Related Collections
Right arrow Vasculitis
Right arrow Diagnostics and Imaging Procedures
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 1313-1317
© 2002 British Society for Rheumatology

Original Papers

A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis

E. Csernok, D. Ahlquist, S. Ullrich and W. L. Gross

Department of Rheumatology, University of Lübeck and Rheumaklinik Bad Bramstedt, Germany

Objective. To evaluate the performance of 11 commercial enzyme-linked immunosorbent assay (ELISA) kits for the detection of antineutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3 (PR3) and myeloperoxidase (MPO) in patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA).

Methods. Serum samples were taken from 92 patients with a histological and clinical diagnosis of WG (n=50) or MPA (n=42) and from 30 disease controls (systemic lupus erythematosus, n=15; rheumatoid arthritis, n=15) and 30 healthy controls. Each of the sera was tested for the presence of ANCA directed against PR3 and MPO using 11 commercially available direct ELISA kits, our in-house PR3- and MPO-ANCA capture ELISAs, and the indirect immunofluorescence technique (IFT).

Results. In tests for WG using PR3-ANCA, the commercial direct ELISA kits differed widely in their sensitivity (from 22 to 70%) and negative predictive value (NPV) (from 43 to 70%), but only moderately in their specificity (from 93 to 100%) and positive predictive value (PPV) (from 93 to 100%). The highest sensitivity (74%) and specificity (100%) for PR3-ANCA were obtained with the in-house capture ELISA. Similar differences and trends were noted for MPO-ANCA assays. Diagnostic sensitivity was more than 60% for four and at least 50% for six of the 11 ELISA kits. The PPV varied from 84 to 100% and the NPV from 58 to 70%. In tests for MPA, the MPO-ANCA ELISA kit designated F and the in-house capture ELISA were best (both had sensitivity 62% and specificity 100%). For both WG and MPA, maximum sensitivity for ANCA was obtained with IFT (80 and 70% respectively).

Conclusion. Determination of PR3-ANCA and MPO-ANCA with the commercial direct ELISA kits achieved poor sensitivity for both WG and MPA. The in-house PR3 and MPO-ANCA capture ELISAs performed better than the commercial ELISAs, combining higher specificity with similar sensitivity. IFT remains the best method for ANCA detection in both diseases.

KEY WORDS: ANCA, Wegener's granulomatosis, Microscopic polyangiitis, Proteinase 3, Myeloperoxidase, ELISA.

Correspondence to: E. Csernok, Oskar-Alexander-Strasse 26, 24576 Bad Bramstedt, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
T. J. Bedient, M. I. Schwarz, S. D. Groshong, and E. D. Chan
A 45-Year-Old Man With a History of Hepatitis C and Testicular Cancer Presents With Cavitary Lung Lesions and Palpable Purpura
Chest, October 1, 2009; 136(4): 1168 - 1174.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J U Holle, B Hellmich, M Backes, W L Gross, and E Csernok
Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?
Ann Rheum Dis, December 1, 2005; 64(12): 1773 - 1779.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
G. S. Hoffman and C. A. Langford
Are There Different Forms of Life in the Antineutrophil Cytoplasmic Antibody Universe?
Ann Intern Med, November 1, 2005; 143(9): 683 - 685.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M Trevisin, P Neeson, and J Savige
The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs
J. Clin. Pathol., March 1, 2004; 57(3): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Csernok, J. Holle, B. Hellmich, J. Willem, C. Tervaert, C. G. M. Kallenberg, P. C. Limburg, J. Niles, G. Pan, U. Specks, et al.
Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study
Rheumatology, February 1, 2004; 43(2): 174 - 180.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.